FDA Expands Orphan Drug Designation for SurVaxM, Immunotherapy Developed at Roswell Park
FDA Expands Orphan Drug Designation for SurVaxM, Immunotherapy Developed at Roswell Park
Orphan status for cancer treatment vaccine now applies to use to treat malignant gliomas in children and adults
Details
More Products & Services
People
People
Description
HIGHLIGHTS
- New designation broadens potential use of vaccine as treatment for glioma
- Nationwide trials continue in adults, children with some brain tumors
- Development of SurVaxM made possible by community donations
- New designation broadens potential use of vaccine as treatment for glioma
- Nationwide trials continue in adults, children with some brain tumors
- Development of SurVaxM made possible by community donations
Share
Recent Chats
Share via email
Future: handle WhatsApp here
Future: handle LinkedIn here
Future: handle Twitter here
SUBMENU HERE
Share via Chat
Copy Link
You've reached your free preview limit
Create an account to continue exploring
Currently viewing: International Medical Concierge Program
Preview limit reached
Continue exploring
You've reached your free preview limit
Unlock full access
Continue Exploring
Continue Exploring
Create an account to find in-depth information on thousands of companies, people and products in your industry
- Find the right companies and products ... fast
- Bookmark events, companies, people and products you are interested in
- Message company representatives directly
- Plan ahead for upcoming shows you are attending
Already have an account? Sign in
Free to use · No spam · Built for professionals